Tech Company Financing Transactions

SQZ Biotechnologies Funding Round

On 5/19/2020, SQZ Biotechnologies raised $65 million in Series D funding from Temasek Holdings, GV and Illumina Ventures.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

200 Arsenal Yards Blvd.
Watertown, MA 02472
USA

Phone

(617) 758-8672

Website

www.sqzbiotech.com

Email Address

[email protected]

Overview

SQZ Biotechnologies (Nasdaq: SQZ). Many promising therapeutic modalities have limited clinical efficacy due to the challenges of delivering molecules into cells. SQZ Biotech seeks to address this fundamental problem by developing its CellSqueeze platform for use in drug discovery and clinical applications.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Armon Sharei

        

Chief Financial Officer

Teri Loxam

        

Chief Medical Officer

Oliver Rosen

        

Chief Scientific Officer

Howard Bernstein

        

Vice President

Katherine Seidl

        

Vice President

Marija Tadin-Strapps

        

VP - Finance

Alex Balcom

        

VP - General Counsel

Larry Knopf

        

VP - Human Resources

David First

        

VP - Regulatory Affairs

Nicole D'Auteuil

        

Browse more venture capital transactions:

Prev: 5/19/2020: Nanotech Energy venture capital transaction
Next: 5/20/2020: PresenceLearning venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary